Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 10/20 | 0.78 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.63 |
| ▸ | GPR174 | Q9BXC1 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29059592 | 1.00 | P2RY10 (0.78) | P2RY10GPR34GPR174 | |
| SCHEMBL29285069 | 0.96 | P2RY10 (0.72) | P2RY10GPR34GPR174 | |
| SCHEMBL30763305 | 0.93 | P2RY10 (0.67) | P2RY10GPR34GPR174 | |
| SCHEMBL4291753 | 0.93 | P2RY10 (0.67) | P2RY10GPR34GPR174 | |
| SCHEMBL28614391 | 0.93 | P2RY10 (0.67) | P2RY10GPR34GPR174 | |
| SCHEMBL609831 | 0.92 | P2RY10 (0.65) | P2RY10GPR34GPR174 | |
| SCHEMBL29238665 | 0.92 | P2RY10 (0.65) | P2RY10GPR34GPR174 | |
| SCHEMBL29441339 | 0.89 | P2RY10 (0.63) | P2RY10GPR34 | |
| SCHEMBL1921456 | 0.89 | P2RY10 (0.75) | P2RY10GPR34GPR174 | |
| SCHEMBL29042659 | 0.89 | P2RY10 (0.75) | P2RY10GPR34GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338495-A1 | Vaccine Compositions and Antibodies For Lyme Disease | Vitruviae LLC | 2023-10-26 | — | — | US | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| EP-4200330-A2 | VACCINE COMPOSITIONS AND ANTIBODIES FOR LYME DISEASE | Vitruviae LLC (US) | 2023-06-28 | — | — | EP | claimed |
| WO-2022255701-A1 | LIPOPROTEIN-MIMICKING SOLID LIPID NANOPARTICLES FOR DRUG DELIVERY AND USES THEREOF | 주식회사 티온랩테라퓨틱스 | 2022-12-08 | — | — | WO | claimed |
| WO-2022040429-A2 | VACCINE COMPOSITIONS AND ANTIBODIES FOR LYME DISEASE | Vitruviae LLC (US) | 2022-02-24 | — | — | WO | claimed |
| US-20150297749-A1 | LOW-DENSITY LIPOPROTEIN ANALOGUE NANOPARTICLES, AND COMPOSITION COMPRISING SAME FOR TARGETED DIAGNOSIS AND TREATMENT OF LIVER | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2015-10-22 | — | — | US | claimed |
| EP-4400169-A2 | RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | Vico Therapeutics B.V. (NL) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024136626-A1 | CYCLOALKANE-BASED LIPID COMPOUND FOR DELIVERING NUCLEIC ACIDS, AND LIPID NANOPARTICLES COMPRISING SAME | 주식회사 녹십자 | 2024-06-27 | — | — | WO | disclosed |
| EP-3604536-B1 | RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | VICO THERAPEUTICS B V (NL) | 2024-05-29 | — | — | EP | disclosed |
| US-20230330128-A1 | OLIGOMERS HAVING BICYCLIC SCAFFOLD MOIETIES | BIOMARIN TECHNOLOGIES B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| EP-4252845-A2 | PRE-MRNA SPLICE SWITCHING OR MODULATING OLIGONUCLEOTIDES COMPRISING BICYCLIC SCAFFOLD MOIETIES, WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF GENETIC DISORDERS | BioMarin Technologies B.V. (NL) | 2023-10-04 | — | — | EP | disclosed |
| EP-4222262-A1 | ANTISENSE OLIGONUCLEOTIDES TARGETING THE EXON 51 OF DYSTROPHIN GENE | BioMarin Technologies B.V. (NL) | 2023-08-09 | — | — | EP | disclosed |
| US-20230039928-A1 | Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease | PROQR THERAPEUTICS II B.V. (NL) | 2023-02-09 | — | — | US | disclosed |
| WO-2012144906-A1 | NEW COMPOUNDS FOR TREATING, DELAYING AND/OR PREVENTING A HUMAN GENETIC DISORDER SUCH AS MYOTONIC DYSTROPHY TYPE 1 (DM1) | PROSENSA TECHNOLOGIES B.V. (NL) | 2012-10-26 | — | — | WO | disclosed |
| US-20090098574-A1 | FUNCTIONALIZATION OF GOLD NANOPARTICLES WITH ORIENTED PROTEINS, APPLICATION TO THE HIGH-DENSITY LABELLING OF CELL MEMBRANES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2009-04-16 | — | — | US | disclosed |
| US-20080241941-A1 | REAGENT FOR MEASURING CLOTTING TIME AND METHOD FOR STABILIZING TISSUE FACTOR | SYSMEX CORPORATION (JP) | 2008-10-02 | — | — | US | disclosed |
| EP-1975622-A1 | Reagent for measuring clotting time and method for stabilizing tissue factor | Sysmex Corporation (JP) | 2008-10-01 | — | — | EP | disclosed |
| EP-1935902-A1 | Reagent for measuring clotting time and method for manufacturing the reagent | Sysmex Corporation (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080124704-A1 | REAGENT FOR MEASURING CLOTTING TIME AND METHOD FOR MANUFACTURING THE REAGENT | SYSMEX CORPORATION (JP) | 2008-05-29 | — | — | US | disclosed |
| CN-101183109-A | Reagent for measuring clotting time and method for manufacturing the reagent | SYSMEX CORP (JP) | 2008-05-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330128-A1 | OLIGOMERS HAVING BICYCLIC SCAFFOLD MOIETIES | SMN1; SMN2, RBM17, RBM22 | P2RY10 3603/4885GPR34 3366/4885GPR174 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.